Dose: 0.01 to 0.02 mg/kg
Single Dose: 0.015 (0.015)
Frequency: 8 hourly
Route: Inhalation
Instructions:

Dose: 0.5 to 1 mg/kg
Single Dose: 0.75 (0.75)
Frequency: 8 hourly
Route: Oral
Instructions: -

Dose: 0.075 mg/kg
Single Dose: 0.075 (0.075)
Frequency: 8 hourly
Route: Inhalation
Instructions: -

Orciprenaline (Sulphate) also known as Metaproterenol. . It is of Synthetic origin and belongs to Benzenediol. It belongs to Beta-2 adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Bronchodilator pharmacological group.The Molecular Weight of Orciprenaline (Sulphate) is 520.60. Its pKa is Slightly soluble.

Orciprenaline (Sulphate) is contraindicated in conditions like Cardiac arrhythmia,Diabetes mellitus,Myocardial infarction,Thyrotoxicosis,Ischaemic heart disease,Cystic fibrosis,Aortic stenosis,Quadriplegia.

The severe or irreversible adverse effects of Orciprenaline (Sulphate), which give rise to further complications include Intolerable muscle tremors, Extra systoles.Orciprenaline (Sulphate) produces potentially life-threatening effects which include Ventricular arrhythmias, Deterioration of asthma. which are responsible for the discontinuation of Orciprenaline (Sulphate) therapy.The signs and symptoms that are produced after the acute overdosage of Orciprenaline (Sulphate) include Nausea, Tachycardia, Headache, Tremor, Restlessness, Anxiety, BP changes, Excitement.The symptomatic adverse reactions produced by Orciprenaline (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Palpitation, Tachycardia, Nervousness, SweatingX, Hypotension, Tremor, Taste disturbance, Hypokalemia, Hyperglycemia, nervousness, Nervousness, dizziness, Hypotension, Tachycardia.

Orciprenaline (Sulphate) is primarily indicated in conditions like Asthma, Bronchitis, Obstructive airway disease, and can also be given in adjunctive therapy as an alternative drug of choice in Bradycardia, Reversible airways obstruction.

No data regarding the interactions of Orciprenaline (Sulphate) was found.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Aerosol Store Below 25°C. Protect from Sunlight, Moisture and Heat. Store in a well closed container.

Orciprenaline should not be used in the patient with hypothyroidism, diabetes mellitus, hypertension, cardiac arrhythmias, ischemic heart disease, seizures or hypersensitivity to sympathomometics (pheochromocytoma). The safe use of drug during pregnancy has not been established. The inhaled Orciprenaline should be used with great caution in the children under the age of 12 years.